Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc > VIR future

<< Previous

Bullboard Posts

Next >>

Comment by theshadow39on May 17, 2019 12:11am

122 Views

Post# 29754263

RE:VIR future

Some quick dd

1. Cultivation licence
2. Sales licence
3. Oil production licence
3. 79 strains, with more being developed by an institutional partnership.
4. One of their strains won the Amsterdam cannabis cup
5. Grow these elite strains in other micro and LP facilities on a buy back program.
6. Have demonstrated pill capability with a broken coast joint venture.
7. 10 acre plot of land to expand on
8. ~11mn in the bank
9. No debt.
10. Germany export jv

Do your own dd but I’m happy with my fairly recent investment potential.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading